Evidence map›Paper›PMID 29744297›Full record

ArticleFEBS open bio2018

FGF-2 suppresses expression of nephronectin via JNK and PI3K pathways.

Tadashi Kato, Atsushi Yamada, Mikiko Ikehata, Yuko Yoshida, Kiyohito Sasa, Naoko Morimura, Akiko Sakashita, Takehiko Iijima, Daichi Chikazu, Hiroaki Ogata and 1 more

Open access · goldAbstract read
In one paragraph

Article in FEBS open bio, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Role of Nephronectin in Pathophysiology of Silicosis.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Tadashi KatoDepartment of Biochemistry School of Dentistry Showa University Tokyo Japan.
Atsushi YamadaDepartment of Biochemistry School of Dentistry Showa University Tokyo Japan.
Mikiko IkehataDepartment of Biochemistry School of Dentistry Showa University Tokyo Japan.
Yuko YoshidaDepartment of Biochemistry School of Dentistry Showa University Tokyo Japan.
Kiyohito SasaDepartment of Biochemistry School of Dentistry Showa University Tokyo Japan.
Naoko MorimuraDepartment of Integrative Physiology Shiga University of Medical Science Japan.
Akiko SakashitaDepartment of Internal Medicine Showa University Yokohama Northern Hospital Japan.
Takehiko IijimaDepartment of Perioperative Medicine Division of Anesthesiology School of Dentistry Showa University Tokyo Japan.
Daichi ChikazuDepartment of Oral and Maxillofacial Surgery Tokyo Medical University Japan.
Hiroaki OgataDepartment of Internal Medicine Showa University Yokohama Northern Hospital Japan.
Ryutaro KamijoDepartment of Biochemistry School of Dentistry Showa University Tokyo Japan.
Showa University · JPShowa University Northern Yokohama Hospital · JPShiga University of Medical Science · JPTokyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nephronectin (Npnt), an extracellular matrix protein, is a ligand for integrin α8β1 and is involved in the development of various organs, such as the kidneys, bones, liver, and muscles. Previously, we found that Npnt expression was inhibited by various cytokines including transforming growth factor-β (Tgf-β) and oncostatin M (Osm). Fibroblast growth factor (Fgf)-2, otherwise known as basic Fgf, also plays important roles in skeletal development and postnatal osteogenesis. In this study, Npnt expression was found to be suppressed by Fgf-2 in MC3T3-E1 cells, an osteoblast-like cell line, in a dose- and time-dependent manners. Furthermore, Fgf-2-mediated

Indexed as

fibroblast growth factor‐2Jun N‐terminal kinaseMC3T3‐E1nephronectinphosphoinositide‐3 kinase

Identifiers

PMID29744297
PMCPMC5929927
OpenAlexW2795338278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.